ArticleStudies in history and philosophy of biological and biomedical sciences2017
Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968-2000.
Article in Studies in history and philosophy of biological and biomedical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Article
- A novel nanoparticle vaccine displaying multistage tuberculosis antigens confers protection in mice infected with H37Rv.NPJ vaccines · 2025Article
- Multifaceted virus-like particles: Navigating towards broadly effective influenza A virus vaccines.Current research in microbial sciences · 2025Review
- A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates.Frontiers in immunology · 2024Article
- HBV Vaccines: Advances and Development.Vaccines · 2023Review
- Indian Biosimilars and Vaccines at Crossroads-Replicating the Success of Pharmagenerics.Vaccines · 2023Review
- Hepatitis B eradication: vaccine as a key player.American journal of translational research · 2023Review
- Review of Developments in Combating COVID-19 by Vaccines, Inhibitors, Radiations, and Nonthermal Plasma.Current issues in molecular biology · 2022Review
- Epidemiological and clinical aspects of hepatitis B virus infection in Italy over the last 50 years.World journal of gastroenterology · 2022Review
- AMDV Vaccine: Challenges and Perspectives.Viruses · 2021Review
- Review
- Nanocarrier vaccines for SARS-CoV-2.Advanced drug delivery reviews · 2021Article
- Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021Review
- Capsids of hepatitis B virus e antigen with authentic C termini are stabilized by electrostatic interactions.FEBS letters · 2020Article
- Identification and characterization of protective CD8Immunity, inflammation and disease · 2020Article
- Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.Viruses · 2020Review
- Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.Frontiers in immunology · 2020Review
- Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy.Frontiers in immunology · 2020Review
- Cuts and the cutting edge: British science funding and the making of animal biotechnology in 1980s Edinburgh.British journal for the history of science · 2017Article
- The Requisiteness for not Sacrificing Medical Biotechnology in the Coronavirus Era.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The approval, from 1986, of a series of recombinant hepatitis B vaccines was a landmark both in the growth of biotechnology and in the development of the vaccine innovation system. In this paper, we show how the early development of the hepatitis B vaccines was shaped by a political and economic context that newly favoured commercialisation of academic research, including the appropriation and management of intellectual property; we elucidate the contingent interests and motivations that led new biotechnology companies and established pharmaceutical businesses to invest in developing recombinant vaccines specifically against hepatitis B; and we show how these and other factors combined to make those vaccines an unexpected commercial success. Broadening the scope of our analysis to include not just North America and Europe but also low- and middle-income countries, we show how the development of the hepatitis B vaccines facilitated the emergence of a two-tier innovation system structured by tensions between the demands for commercial profitability on the one hand, and the expectation of public health benefit for low- and middle-income countries on the other.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.